Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma.
Biomarker
Merkel cell carcinoma
Neutrophil-to-lymphocyte ratio
Pan-immune-inflammation value
Platelet-to-lymphocyte ratio
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
07
01
2022
accepted:
17
01
2022
pubmed:
1
2
2022
medline:
28
9
2022
entrez:
31
1
2022
Statut:
ppublish
Résumé
We aimed to determine whether the pan-immune-inflammation value (PIV) of patients with Merkel cell carcinoma (MCC) at primary diagnosis differs from controls and whether it is associated with disease stage and outcome. In this retrospective study, we recruited MCC patients with stage I-III. PIV was calculated from absolute complete blood cell counts obtained within one week at MCC diagnosis as follows: [neutrophils (10 The median PIV in MCC patients was significantly increased compared to both CM patients as well as healthy controls. PIV of MCC patients in stage II and III was significantly higher compared to stage I patients. ROC analysis revealed that MCC recurrence was significantly associated with a PIV greater than 372 [p < 0.0001, Youden index 0.58; hazard ratio: 4 (95% confidence interval: 1.7 to 9.2)]. In multivariate analysis, only a PIV greater than 372 and higher MCC stage were determined as independent predictors for disease recurrence. We determined, for the first time, the prognostic ability of the promising blood-based biomarker PIV in MCC patients and observed that PIV is increased in MCC patients in dependence on disease stage and independently predicts MCC recurrence.
Identifiants
pubmed: 35098389
doi: 10.1007/s00432-022-03929-y
pii: 10.1007/s00432-022-03929-y
pmc: PMC9508022
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3183-3189Informations de copyright
© 2022. The Author(s).
Références
J Nucl Med. 2021 May 10;62(5):605-611
pubmed: 33579807
Cancer Treat Rev. 2015 Dec;41(10):971-8
pubmed: 26481060
Int J Mol Sci. 2021 May 23;22(11):
pubmed: 34071045
J Dtsch Dermatol Ges. 2019 May;17(5):562-576
pubmed: 31056838
Nat Rev Dis Primers. 2017 Oct 26;3:17077
pubmed: 29072302
Stat Med. 2008 Jan 30;27(2):297-315
pubmed: 17624866
J Cancer Res Clin Oncol. 2022 Nov;148(11):3103-3108
pubmed: 35006344
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33879601
Br J Dermatol. 2016 Jan;174(1):146-51
pubmed: 26343230
Sci Rep. 2018 Jul 12;8(1):10566
pubmed: 30002404
Clin Chem. 2019 Mar;65(3):462-472
pubmed: 30626636
Cancer Immunol Immunother. 2020 Apr;69(4):559-568
pubmed: 31974724
Br J Cancer. 2020 Aug;123(3):403-409
pubmed: 32424148
Clin Transl Oncol. 2021 Feb;23(2):311-317
pubmed: 32562197
Target Oncol. 2021 Jul;16(4):529-536
pubmed: 34076798
Cancers (Basel). 2020 Apr 06;12(4):
pubmed: 32268526
Oncotarget. 2015 Sep 22;6(28):26472-82
pubmed: 26299616
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12
pubmed: 24793958
Eur J Cancer. 2021 Jun;150:155-167
pubmed: 33901794
Mod Pathol. 2019 Sep;32(9):1359-1372
pubmed: 30976104
Int J Clin Oncol. 2019 Oct;24(10):1301-1310
pubmed: 31073814
Sci Rep. 2021 Jul 19;11(1):14662
pubmed: 34282214
J Am Acad Dermatol. 2016 Oct;75(4):712-721.e1
pubmed: 27544490
Curr Pharm Des. 2015;21(21):3032-40
pubmed: 26004407
Br J Dermatol. 2019 Aug;181(2):389-390
pubmed: 30703276
Clin Cancer Res. 2021 May 1;27(9):2494-2504
pubmed: 33547200
Oncotarget. 2017 Jun 29;8(43):75381-75388
pubmed: 29088873
J Am Acad Dermatol. 2018 Jul;79(1):165-167.e2
pubmed: 29544740
Front Immunol. 2021 Oct 29;12:724443
pubmed: 34777341
Oncotarget. 2018 Oct 19;9(82):35293-35299
pubmed: 30450158
Radiol Oncol. 2021 May 31;55(3):347-353
pubmed: 34051707